# A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Source: https://onco.cc/trials/nct02717611/  
OnCo record `nct02717611` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acalabrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy is a phase 2 interventional study registered as NCT02717611 by Acerta Pharma BV, with 60 participants enrolled, started 2016-03-08 and due to reach its primary completion in 2020-10-16. Interventions recorded: ACP-196 (acalabrutinib). Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02717611
- Phase: 2
- Setting: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
- Sponsor: Acerta Pharma BV
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT02717611: https://clinicaltrials.gov/study/NCT02717611

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct02717611.json